Molecular Oncology

Article	Citations
Issue Information	227
	113
Issue Information	106
	95
Corrigendum to: Small proline‐rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage‐induced apoptosis	83
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1	72
TGFβ selects for pro‐stemness over pro‐invasive phenotypes during cancer cell epithelial–mesenchymal transition	71
Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities	68
Cancer‐associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T‐cell suppression	65
Correction to “Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition”	58
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas	58
Correction to “SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression”	57
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2+ mononuclear phagocyte differentiation in liver cancer	57
NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy	46
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 4	44
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy	42
Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo	40
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer	40
An arms‐race against resistance: leukemic stem cells and lineage plasticity	39
Gene signature predicting recurrence in oral squamous cell carcinoma is characterized by increased oxidative phosphorylation	37
Microglia limit brain tumor development by restricting tumor cell proliferation and inducing T‐cell immunity	35
Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors	35
Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling	35
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer	34
Precision Cancer Medicine 2.0—Oncology in the postgenomic era	34

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma	32
Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma	32
Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread	32
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO	31
Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system	31
Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detection	31
Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment	30
PoDCall: a robust tool for automated droplet classification in DNA‐methylation droplet digital PCR	29
ERK signaling controls productive HIF‐1 binding to chromatin and cancer cell adaptation to hypoxia through HIF‐1α interaction with NPM1	29
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM	28
Issue Information	28
Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer	27
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity	26
Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer	26
The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis	26
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1–NDRG1 deregulation	26
Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC	25
RETRACTION: Long Noncoding RNA ZNF667‐AS1 Reduces Tumor Invasion and Metastasis in Cervical Cancer by Counteracting Microrna‐93‐3p‐Dependent PEG3 Downregulation	25
Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma	25
Issue Information	25
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models	25
Academia and society should join forces to make anti‐cancer treatments more affordable	24
Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer	24
Disruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis	24
Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor	24
Hijacking the BAF complex: the mechanistic interplay of ARID1A and EWS::FLI1 in Ewing sarcoma	24
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer	23
ANGPTL2‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion	23
New retinoblastoma (RB) drug delivery approaches: anti‐tumor effect of atrial natriuretic peptide (ANP)‐conjugated hyaluronic‐acid‐coated gold nanoparticles for intraocular treat	23
Cancer cachexia: biomarkers and the influence of age	23
Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer	23
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia	23
Correction to: Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C	23
Germline variants in CDKN2A wild‐type melanoma prone families	22
RNA polymerase I inhibition induces terminal differentiation, growth arrest, and vulnerability to senolytics in colorectal cancer cells	22
The LIN28B–let‐7–PBK pathway is essential for group 3 medulloblastoma tumor growth and survival	22
A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma	22
T2R bitter taste receptors regulate apoptosis and may be associated with survival in head and neck squamous cell carcinoma	22
LncRNA miR205HG hinders HNRNPA0 translation: anti‐oncogenic effects in esophageal carcinoma	22
Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migration	22
The transcribed ultraconserved region uc.160+ enhances processing and A‐to‐I editing of the miR‐376 cluster: hypermethylation improves glioma prognosis	22
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients	22
Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T‐cell receptor sequencing	21
Issue Information	21
Retraction statement: Consistency analysis of microRNA‐arm expression reveals microRNA‐369‐5p/3p as tumor suppressors in gastric cancer	21
	20
Replenishing co‐downregulated miR‐100‐5p and miR‐125b‐5p in malignant germ cell tumors causes growth inhibition through cell cycle disruption	20
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma	20
Issue Information	20
Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers	19

Correction to “The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma”	19
DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC	19
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK<	19
Sustained cancer‐relevant alternative RNA splicing events driven by PRMT5 in high‐risk neuroblastoma	19
Issue Information	19
Tetraploidy‐linked sensitization to CENP‐E inhibition in human cells	19
NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR‐Akt feedback loop that activates autophagy	19
Correction to “The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion”	18
	18
Cancer as an infective disease: the role of EVs in tumorigenesis	17
MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness	17
Cancer outcome research – a European challenge Part II: Opportunities and priorities	17
Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR<	17
Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment	17
Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR)	17
FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas	17
SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF‐β‐independent manner	17
Post‐prostatic‐massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostate‐cancer‐typical microRNAs and activate proto‐oncogenes	17
Abstracts	16
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients	16
Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models	16
Targeting protein folding in N‐Myc‐driven medulloblastoma	16
DNA repair as a shared hallmark in cancer and ageing	16
Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors	16
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential	16
Long noncoding RNAs with peptide‐encoding potential identified in esophageal squamous cell carcinoma: KDM4A‐AS1‐encoded peptide weakens cancer cell viability and migratory capacity	16
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma	16
Rodent models of tumours of the central nervous system	16
Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers	16
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies	16
Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer	15
Assembly of glioblastoma tumoroids and cerebral organoids: a 3Din vitro model for tumor cell invasion	15
Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study	15
Lung cancer cells expressing a shortened CDK16 3′UTR escape senescence through impaired miR‐485‐5p targeting	15
Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation	15
A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL‐13Rα2‐mediated JNK‐AP‐1 signals	15
Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience	15
CHML is an NRF2 target gene that regulates mTOR function	15
Assay‐agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple‐negative breast cancer	15
KRAS inhibitors: going noncovalent	15
Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach	15
	14
Retraction Statement: Circ‐TCF4.85 silencing inhibits cancer progression through microRNA‐486‐5p‐targeted inhibition of ABCF2 in hepatocellular carcinoma	14
PP2A‐based triple‐strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells	14
Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial	14
Elucidating prognostic significance of purine metabolism in colorectal cancer through integrating data from transcriptomic, immunohistochemical, and single‐cell RNA sequencing analysis	14
A rapid, multiplex digital PCR assay to detect gene variants and fusions in non‐small cell lung cancer	14
Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance	14
Microglia and macrophages in glioblastoma: landscapes and treatment directions	14
Issue Information	14
Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models	14
Issue Information	14
The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma	14
USP35 mitigates endoplasmic reticulum stress‐induced apoptosis by stabilizing RRBP1 in non‐small cell lung cancer	14
Issue Information	13
Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial	13
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs	13
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1	13
Targeting senescence as an anticancer therapy	13
SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma	13
Issue Information	13
Liver X receptors induce antiproliferative effects in basal‐like breast cancer	13
PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis	13
Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells	13
Targeting cellular senescence to combat cancer and ageing	13
Protein palmitoylation in cancer: molecular functions and therapeutic potential	13
Simultaneous detection of eight cancer types using a multiplex droplet digital PCR assay	13
cAMP‐phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression	13
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma	13
Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer	13
Lipid metabolism in B cell biology	13
SKA1 promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy	12
Postbiotics of Lacticaseibacillus paracaseiCECT 9610 and Lactiplantibacillus plantarumCECT 9608 attenuates store‐operated calcium entry and FAK phosphory	12
From bedside to portable and wearable: development of a conformable ultrasound patch for deep breast tissue imaging	12
Copy number variations contribute to malignant tumor development in children with serious birth defects	12
Thioredoxin‐interacting protein (TXNIP) is a substrate of the NEDD4‐like E3 ubiquitin‐protein ligase WWP1 in cellular redox state regulation of acute myeloi	12
The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma	12
Metabolism in the tumor cell and beyond	12
Issue Information	12
SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma	12

The invariant chain CD74 protein is a cell surface binding partner of TIMP‐1 in breast cancer cells	12
Issue Information	11
Comprehensive profiling of lncRNAs and mRNAs enriched in small extracellular vesicles for early noninvasive detection of colorectal cancer: diagnostic panel assembly and extensiv	11
Current status of precision oncology in adult glioblastoma	11
Enhanced reversal of ABCG2‐mediated drug resistance by replacing a phenyl ring in baicalein with a meta‐carborane	11
GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL	11
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation	11
Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β‐catenin signaling and tumor growth	11
ARID1A‐deficient cells require HDAC6 for progression of endometrial carcinoma	11
	11
Nicotinamide (niacin) supplement increases lipid metabolism and ROS‐induced energy disruption in triple‐negative breast cancer: potential for drug repositioning as an anti‐tumor agent	11
Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome	11
Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia	11
CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma	11
Immune escape of colorectal tumours via local LRH‐1/Cyp11b1‐mediated synthesis of immunosuppressive glucocorticoids	11
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy	11
	11
	11
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework	11
Immune evasion: An imperative and consequence of MYC deregulation	11
Expression of Concern: T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma	11
Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice	11
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients	11
Fragment‐based drug discovery—the importance of high‐quality molecule libraries	11
Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis	10
Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study	10
The roles and applications of extracellular vesicles in cancer	10
Transcriptomic pan‐cancer analysis using rank‐based Bayesian inference	10
Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long‐term follow‐up of the SweBCG91RT rand	10
Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment	10
Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade	10
Identifying the personalized driver gene sets maximally contributing to abnormality of transcriptome phenotype in glioblastoma multiforme individuals	10
LIM domain‐containing protein Ajuba inhibits chemotherapy‐induced apoptosis by negatively regulating p53 stability in colorectal cancer cells	10
Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study	10
Resistance prediction in high‐grade serous ovarian carcinoma with neoadjuvant chemotherapy using data‐independent acquisition proteomics and an ovary‐specific spectral library	10
Thermal proteome profiling and proteome analysis using high‐definition mass spectrometry demonstrate modulation of cholesterol biosynthesis by next‐generation galeterone analog VNPP433‐3β i	10
Integrated analysis of racial disparities in genomic architecture identifies a trans‐ancestry prognostic subtype in bladder cancer	10
Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity	10
Bovine meat and milk factor protein expression in tumor‐free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival	9
Lipopolysaccharide from the commensal microbiota of the breast enhances cancer growth: role of S100A7 and TLR4	9
Interferon regulatory factor 4 modulates epigenetic silencing and cancer‐critical pathways in melanoma cells	9
Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTOR	9
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer	9
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives	9
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers	9
Deciphering metabolic crosstalk in context: lessons from inflammatory diseases	9
	9
miR‐200a/b/‐429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer	9
Identification and targeting of a HES1‐YAP1‐CDKN1C functional interaction in fusion‐negative rhabdomyosarcoma	9
Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy	9
The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation	9
PPM1D activity promotes the replication stress caused by cyclin E1 overexpression	9
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care	9
Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells	9
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib	9
Enhancing therapeutic efficacy in triple‐negative breast cancer and melanoma: synergistic effects of modulated electro‐hyperthermia (mEHT) with NSAIDs especially COX‐2 inhibition in in vivo mod	9
Investigation of somatic mutation profiles and tumor evolution of primary oropharyngeal cancer and sequential lymph node metastases using multiregional whole‐exome sequencing	9
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAFV600E mutated colorectal cancer—results from the FIRE‐4.5 study	9
Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location	9
Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities	9
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype	9
Viral mimicry evasion: a new role for oncogenic KRAS mutations	9
Overexpression of the pro‐protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling	9
Sortilin‐related receptor is a druggable therapeutic target in breast cancer	9
Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis	9
Malformin C preferentially kills glioblastoma stem‐like cells via concerted induction of proteotoxic stress and autophagic flux blockade	8
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration	8
Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance	8
Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product	8
hnRNP‐A1 binds to the IRES of MELOE‐1 antigen to promote MELOE‐1 translation in stressed melanoma cells	8
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications	8
Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients	8
In the spotlight: Julio Celis, the Founding Editor of Molecular Oncology	8
Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction	8
Issue Information	8
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer	8
Proximity proteomics reveals role of Abelson interactor 1 in the regulation of TAK1/RIPK1 signaling	8
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?	8
PP2A methylesterase PME‐1 suppresses anoikis and is associated with therapy relapse of PTEN‐deficient prostate cancers	8
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management	8
Expression pattern of secretory‐cell‐related transcriptional signatures in colon adenocarcinomas defines tumor microenvironment characteristics and correlates with clinical outcomes	8
	8
The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging‐related disease	8
Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study	8
High CD34 surface expression in BCP‐ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion	8
Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma	8
Screening of an annexin‐A2‐targeted heptapeptide for pancreatic adenocarcinoma localization	8
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials	8
Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA/N2 NSCLC	8